| Dr Justin Robert Cramer, MD | |
|
1825 Atchison Ave, Marshall, MO 65340-9752 | |
| (660) 886-8584 | |
| (888) 979-8868 |
| Full Name | Dr Justin Robert Cramer |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 24 Years |
| Location | 1825 Atchison Ave, Marshall, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114969292 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 2002027106 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Kindred At Home | Columbia, MO | Home health agency |
| Fitzgibbon Memorial Hospital | Marshall, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Regional Health Care Clinic Inc | 8224926092 | 21 |
News Archive
Rotavirus infection is thought to be a risk factor for type 1 diabetes mellitus (T1DM). The role played by live attenuated rotavirus vaccination in the risk of this condition in children is, therefore, an area of active research. A new study published in the journal JAMA Pediatrics in March 2020 debunks this concern.
AMDL, Inc. has announced that it has received an important Israeli patent for an animal model for the evaluation of vaccines, which is a part of its unique Combination Immune Therapy (CIT) technology.
Osteoarthritis, in the simplest sense, is wear and tear of the cartilage (connecting tissue) of the joints, which results in bones rubbing together, causing pain and stiffness. While other factors, such as genetics, can affect the progression of osteoarthritis, the less strain a person puts on his or her joints, the less likely the cartilage is to deteriorate.
Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in U.S. Application Serial No. 11/977,506 covering methods of antagonizing miR-181a to regulate immune response. This patent is owned by Stanford University and licensed exclusively to Regulus. miR-181a has been shown to regulate the response of immune cells, such as T lymphocytes, to specific stimuli and modulation of miR-181a could lead to a novel treatment of inflammatory disease.
Themis announced today that it has entered into a license agreement with Max-Planck-Innovation GmbH, the technology transfer agency of the Max Planck Society in Germany, granting it exclusive worldwide license to develop, manufacture and commercialize therapies based on an oncolytic measles virus platform that was jointly developed by the Eberhard-Karls-University Tübingen and the Max Planck Institute for Biochemistry. Financial terms of the agreement were not disclosed.
› Verified 9 days ago
| Entity Name | Regional Health Care Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922057504 PECOS PAC ID: 8224926092 Enrollment ID: O20040304001212 |
News Archive
Rotavirus infection is thought to be a risk factor for type 1 diabetes mellitus (T1DM). The role played by live attenuated rotavirus vaccination in the risk of this condition in children is, therefore, an area of active research. A new study published in the journal JAMA Pediatrics in March 2020 debunks this concern.
AMDL, Inc. has announced that it has received an important Israeli patent for an animal model for the evaluation of vaccines, which is a part of its unique Combination Immune Therapy (CIT) technology.
Osteoarthritis, in the simplest sense, is wear and tear of the cartilage (connecting tissue) of the joints, which results in bones rubbing together, causing pain and stiffness. While other factors, such as genetics, can affect the progression of osteoarthritis, the less strain a person puts on his or her joints, the less likely the cartilage is to deteriorate.
Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in U.S. Application Serial No. 11/977,506 covering methods of antagonizing miR-181a to regulate immune response. This patent is owned by Stanford University and licensed exclusively to Regulus. miR-181a has been shown to regulate the response of immune cells, such as T lymphocytes, to specific stimuli and modulation of miR-181a could lead to a novel treatment of inflammatory disease.
Themis announced today that it has entered into a license agreement with Max-Planck-Innovation GmbH, the technology transfer agency of the Max Planck Society in Germany, granting it exclusive worldwide license to develop, manufacture and commercialize therapies based on an oncolytic measles virus platform that was jointly developed by the Eberhard-Karls-University Tübingen and the Max Planck Institute for Biochemistry. Financial terms of the agreement were not disclosed.
› Verified 9 days ago
| Entity Name | Justin Cramer Md Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811448764 PECOS PAC ID: 4486933256 Enrollment ID: O20161118000133 |
News Archive
Rotavirus infection is thought to be a risk factor for type 1 diabetes mellitus (T1DM). The role played by live attenuated rotavirus vaccination in the risk of this condition in children is, therefore, an area of active research. A new study published in the journal JAMA Pediatrics in March 2020 debunks this concern.
AMDL, Inc. has announced that it has received an important Israeli patent for an animal model for the evaluation of vaccines, which is a part of its unique Combination Immune Therapy (CIT) technology.
Osteoarthritis, in the simplest sense, is wear and tear of the cartilage (connecting tissue) of the joints, which results in bones rubbing together, causing pain and stiffness. While other factors, such as genetics, can affect the progression of osteoarthritis, the less strain a person puts on his or her joints, the less likely the cartilage is to deteriorate.
Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in U.S. Application Serial No. 11/977,506 covering methods of antagonizing miR-181a to regulate immune response. This patent is owned by Stanford University and licensed exclusively to Regulus. miR-181a has been shown to regulate the response of immune cells, such as T lymphocytes, to specific stimuli and modulation of miR-181a could lead to a novel treatment of inflammatory disease.
Themis announced today that it has entered into a license agreement with Max-Planck-Innovation GmbH, the technology transfer agency of the Max Planck Society in Germany, granting it exclusive worldwide license to develop, manufacture and commercialize therapies based on an oncolytic measles virus platform that was jointly developed by the Eberhard-Karls-University Tübingen and the Max Planck Institute for Biochemistry. Financial terms of the agreement were not disclosed.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Justin Robert Cramer, MD 821 Westwood Dr, Sedalia, MO 65301-2102 Ph: (660) 826-4774 | Dr Justin Robert Cramer, MD 1825 Atchison Ave, Marshall, MO 65340-9752 Ph: (660) 886-8584 |
News Archive
Rotavirus infection is thought to be a risk factor for type 1 diabetes mellitus (T1DM). The role played by live attenuated rotavirus vaccination in the risk of this condition in children is, therefore, an area of active research. A new study published in the journal JAMA Pediatrics in March 2020 debunks this concern.
AMDL, Inc. has announced that it has received an important Israeli patent for an animal model for the evaluation of vaccines, which is a part of its unique Combination Immune Therapy (CIT) technology.
Osteoarthritis, in the simplest sense, is wear and tear of the cartilage (connecting tissue) of the joints, which results in bones rubbing together, causing pain and stiffness. While other factors, such as genetics, can affect the progression of osteoarthritis, the less strain a person puts on his or her joints, the less likely the cartilage is to deteriorate.
Regulus Therapeutics Inc. announced today that the United States Patent and Trademark Office (USPTO) has allowed claims in U.S. Application Serial No. 11/977,506 covering methods of antagonizing miR-181a to regulate immune response. This patent is owned by Stanford University and licensed exclusively to Regulus. miR-181a has been shown to regulate the response of immune cells, such as T lymphocytes, to specific stimuli and modulation of miR-181a could lead to a novel treatment of inflammatory disease.
Themis announced today that it has entered into a license agreement with Max-Planck-Innovation GmbH, the technology transfer agency of the Max Planck Society in Germany, granting it exclusive worldwide license to develop, manufacture and commercialize therapies based on an oncolytic measles virus platform that was jointly developed by the Eberhard-Karls-University Tübingen and the Max Planck Institute for Biochemistry. Financial terms of the agreement were not disclosed.
› Verified 9 days ago
Richard Raynor, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2105 E Watermill Rd, Marshall, MO 65340 Phone: 660-886-6730 | |
Mica K Newman-koehn, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2303 S Highway 65, Marshall, MO 65340 Phone: 660-886-3364 Fax: 660-886-6044 | |
Dr. Kurt Schroer, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2305 S Highway 65 Bldg A, Marshall, MO 65340 Phone: 660-886-7800 Fax: 660-831-3328 | |
Dr. Jared Karl Romney, D.O. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 2305 S Highway 65, Marshall, MO 65340 Phone: 660-886-7431 Fax: 660-831-3325 | |
Dr. Andrew Scott Grivas Jr., Family Medicine Medicare: May Accept Medicare Assignments Practice Location: 1674 S Odell Ave Ste B, Marshall, MO 65340 Phone: 660-229-0858 | |
Dr. Sonal Patel Brizendine, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 2305 South 65 Highway, Building A, Marshall, MO 65340 Phone: 660-886-7800 Fax: 660-831-3328 |